{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:40:12Z","timestamp":1786466412216,"version":"build-2736575974"},"reference-count":40,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Prothrombin complex concentrates (PCC) are used off-label to treat direct factor Xa inhibitor (FXaI)\u2013associated bleeding or to optimize hemostasis before urgent surgery. The Global Assessment of Hemostatic TGA Indices Following the Use of Prothrombin Complex Concentrates for Major Bleeding or Urgent Surgery in Patients Treated with Factor Xa Inhibitors (GAUGE) study is a prospective observational cohort study of the effects of PCC on thrombin generation and hemostasis in FXaI-treated patients. FXaI-treated patients who presented with major bleeding or needed urgent surgery received PCC (50 IU\/kg). Platelet-poor plasma was collected before and after PCC administration. Thrombin generation assay parameters, including lag time (LT), time to peak (TTP), peak thrombin generation (peak), endogenous thrombin potential (ETP), and mean velocity rate index (mVRI) were measured using calibrated automated thrombography. Hemostatic efficacy, thromboembolism, and mortality were adjudicated in duplicate. Multivariable log-linear regression was used to evaluate PCC effects on FXaI levels. Unsupervised k-means clustering was used to identify patients with the largest ETP increment. GAUGE included 101 episodes of FXaI-associated PCC use (FXaI-associated bleeding = 71; urgent surgery = 30). The median PCC dose was 48.0 IU\/kg (interquartile range [IQR], 42.0-50.0). PCC did not affect FXaI levels (P&amp;gt; .05). PCC increased ETP (\u0394868.9 \u00b1 766.6 nM\/min), peak (\u039485.7nM \u00b1 108.2nM), and mVRI (\u039416.5 nM\/min [IQR, 4.4-45.0]). PCC did not affect the LT or TTP (P&amp;gt; .05). Patients in cluster 1 had significantly lower pre-PCC FXaI levels (79 ng\/mL [IQR, 55-93] vs 165 ng\/mL [IQR, 77-219]; P = .009) and a greater \u0394ETP increment (P&amp;lt; .0001) than patients in cluster 2. Effective hemostasis was achieved in 50.0% of major bleeding events (95% confidence interval [CI], 38.4-61.6), and procedural hemostasis was normal in 76.7% of urgent surgeries (95% CI, 59.1-88.2). The 30-day risks of thromboembolism and mortality were 6.9% (95% CI, 3.4-13.6) and 12.9% (95% CI, 7.7-20.8), respectively. PCC increased quantitative thrombin generation without shortening LT or TTP, supporting a prohemostatic effect rather than true FXaI reversal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020203","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:14:03Z","timestamp":1781201643000},"page":"5378-5388","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Effect of PCC on thrombin generation in patients on FXaI with bleeding or needing urgent surgery (GAUGE)"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-7912","authenticated-orcid":false,"given":"Joseph R.","family":"Shaw","sequence":"first","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Gray","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7429-4724","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Le Gal","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-9000","authenticated-orcid":false,"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3401-4086","authenticated-orcid":false,"given":"Roy","family":"Khalife","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3245","authenticated-orcid":false,"given":"Deborah M.","family":"Siegal","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-9368","authenticated-orcid":false,"given":"Lana A.","family":"Castellucci","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-1245","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Delluc","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Gruss\u00e9","sequence":"additional","affiliation":[{"name":"3Diagnostica Stago, Gennevilliers, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Van Dreden","sequence":"additional","affiliation":[{"name":"3Diagnostica Stago, Gennevilliers, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar","family":"Dowlatshahi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katryna","family":"Petersen","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Buyukdere","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Ramsay","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-2972","authenticated-orcid":false,"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"9","key":"2026081110261925700_bib1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2026081110261925700_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/phar.2350","article-title":"Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation","volume":"40","author":"Perreault","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2026081110261925700_bib3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2019000072","article-title":"What we have learned about direct oral anticoagulant reversal","volume":"2019","author":"Siegal","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"14","key":"2026081110261925700_bib4","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of Andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"2026081110261925700_bib5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026081110261925700_bib6","doi-asserted-by":"crossref","first-page":"100100","DOI":"10.1016\/j.bvth.2025.100100","article-title":"Procoagulant off-target effect of the direct oral anticoagulant reversal agent Andexanet alfa","volume":"2","author":"Hoornstra","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"3","key":"2026081110261925700_bib7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jtha.2025.11.003","article-title":"A UK-wide analysis of 2265 patients receiving a reversal agent for direct oral anticoagulant-associated bleeding","volume":"24","author":"Buka","year":"2026","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026081110261925700_bib8","doi-asserted-by":"crossref","first-page":"e2110079","DOI":"10.1001\/jamanetworkopen.2021.10079","article-title":"Availability of specific direct oral anticoagulant reversal agents in US hospitals","volume":"4","author":"Kanjee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026081110261925700_bib9","unstructured":"US Food and Drug Administration\n          . Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication. Accessed 22 January 2026. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/update-safety-andexxa-astrazeneca-fda-safety-communication."},{"issue":"5","key":"2026081110261925700_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026081110261925700_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","article-title":"Management of direct factor Xa inhibitor\u2013related major bleeding with prothrombin complex concentrate: a meta-analysis","volume":"3","author":"Piran","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"2026081110261925700_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"issue":"15","key":"2026081110261925700_bib13","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"2026081110261925700_bib14","doi-asserted-by":"crossref","first-page":"109172","DOI":"10.1016\/j.thromres.2024.109172","article-title":"Prothrombin complex concentrate for direct factor Xa inhibitor-associated bleeding or before urgent surgery","volume":"243","author":"Shaw","year":"2024","journal-title":"Thromb Res"},{"issue":"10","key":"2026081110261925700_bib15","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jtha.2024.07.002","article-title":"Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors","volume":"22","author":"Schulman","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026081110261925700_bib16","first-page":"747","article-title":"Phenotyping the clotting system","volume":"84","author":"Hemker","year":"2000","journal-title":"Thromb Haemost"},{"issue":"3","key":"2026081110261925700_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature","volume":"21","author":"Shaw","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026081110261925700_bib18","doi-asserted-by":"crossref","first-page":"e0293632","DOI":"10.1371\/journal.pone.0293632","article-title":"Thrombin generation, bleeding and hemostasis in humans: protocol for a scoping review of the literature","volume":"18","author":"Shaw","year":"2023","journal-title":"PLoS One"},{"issue":"14","key":"2026081110261925700_bib19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"2026081110261925700_bib20","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1055\/s-0043-1771300","article-title":"Effect of PCC on thrombin generation among patients on factor Xa inhibitors with major bleeding or needing urgent surgery (GAUGE): design and rationale","volume":"7","author":"Shaw","year":"2023","journal-title":"TH Open"},{"issue":"4","key":"2026081110261925700_bib21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026081110261925700_bib22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1747-4949.2010.00579.x","article-title":"Quantomo: validation of a computer-assisted methodology for the volumetric analysis of intracerebral haemorrhage","volume":"6","author":"Kosior","year":"2011","journal-title":"Int J Stroke"},{"issue":"4","key":"2026081110261925700_bib23","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jth.15222","article-title":"Definition of haemostatic effectiveness in interventions used to treat major bleeding: communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Khorsand","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026081110261925700_bib24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"2026081110261925700_bib25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026081110261925700_bib26","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/jth.13815","article-title":"Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study","volume":"15","author":"Song","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2026081110261925700_bib27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/rth2.12418","article-title":"Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation","volume":"4","author":"Lu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2026081110261925700_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bja.2023.10.018","article-title":"Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo","volume":"132","author":"Rayatdoost","year":"2024","journal-title":"Br J Anaesth"},{"issue":"11","key":"2026081110261925700_bib29","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3390\/jcm8111990","article-title":"Rivaroxaban effects illustrate the underestimated importance of activated platelets in thrombin generation assessed by calibrated automated thrombography","volume":"8","author":"Makhoul","year":"2019","journal-title":"J Clin Med"},{"issue":"9","key":"2026081110261925700_bib30","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3390\/jcm9092892","article-title":"Characterization of thrombin generation curve shape in presence of platelets from acute venous thromboembolism patients","volume":"9","author":"Lagrange","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"2026081110261925700_bib31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile","volume":"8","author":"Santagostino","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026081110261925700_bib32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1749-8090-8-154","article-title":"Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article","volume":"8","author":"Bosch","year":"2013","journal-title":"J Cardiothorac Surg"},{"issue":"2","key":"2026081110261925700_bib33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1538-7836.2010.04146.x","article-title":"Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding","volume":"9","author":"Coakley","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026081110261925700_bib34","doi-asserted-by":"crossref","first-page":"e0176967","DOI":"10.1371\/journal.pone.0176967","article-title":"Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing","volume":"12","author":"Bloemen","year":"2017","journal-title":"PloS one"},{"issue":"7","key":"2026081110261925700_bib35","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/STROKEAHA.124.049966","article-title":"Association of biomarkers with intracerebral hematoma expansion and arterial thromboembolic events in patients with acute intracranial hemorrhage: the ANNEXA-I biomarker substudy","volume":"56","author":"Eikelboom","year":"2025","journal-title":"Stroke"},{"issue":"3","key":"2026081110261925700_bib36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/CIRCULATIONAHA.113.003191","article-title":"Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein","volume":"128","author":"Schuijt","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"2026081110261925700_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jth.15589","article-title":"Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa","volume":"20","author":"Maag","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026081110261925700_bib38","doi-asserted-by":"crossref","first-page":"100175","DOI":"10.1016\/j.tru.2024.100175","article-title":"Plasma thrombin generation in the presence of TIX-5 may contribute significantly to a prediction model for major bleeding in patients on VKA anticoagulant therapy","volume":"15","author":"Sol-Maag","year":"2024","journal-title":"Thromb Update"},{"issue":"13","key":"2026081110261925700_bib39","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of Andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"2026081110261925700_bib40","unstructured":"US Food and Drug Administration\n          . FDA Briefing Document: Andexxa (Coagulation Factor Xa [recombinant], Inactivated-zhzo); sBLA 125586\/546. Accessed 4 December 2025. https:\/\/www.fda.gov\/media\/183674\/download?utm_source=."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5378\/2536380\/blooda_adv-2026-020203-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5378\/2536380\/blooda_adv-2026-020203-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:31Z","timestamp":1786463011000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5378\/569098\/Effect-of-PCC-on-thrombin-generation-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":40,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020203","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,31]]}}}